Pimavanserin treatment increases plasma brain-derived neurotrophic factor levels in rats

BACKGROUND: Pimavanserin, a serotonin 5HT-2A receptor inverse agonist is the first-line, FDA-approved treatment of hallucinations and delusions associated with Parkinson’s Disease psychosis (PDP), which occurs in up to 50% of PD patients. The neurobiological mechanism underlying the therapeutic effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tripathi, Ashutosh, Nasrallah, Henry A., Pillai, Anilkumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499044/
https://www.ncbi.nlm.nih.gov/pubmed/37712092
http://dx.doi.org/10.3389/fnins.2023.1237726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499044/
https://www.ncbi.nlm.nih.gov/pubmed/37712092
http://dx.doi.org/10.3389/fnins.2023.1237726

Ejemplares similares